Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
From BIO-Europe, the biggest pharma and biotech partnering meeting in Europe, Scrip lists the five hottest topics of discussion and debate.
Lars Bruening, who recently succeeded Alexander Moscho as Bayer's CEO for the UK and Ireland, talks to Scrip about Brexit uncertainties and fostering the right dialog between pharma and healthcare systems.
Latest From Brexit
London has lost the European Medicines Agency to Amsterdam after the Dutch capital beat Milan in a voting process that ended in the drawing of lots. The Italian pharmaceutical industry was understandably disappointed at losing, but the EMA said the decision “ticked a lot of our boxes” and would help to keep down staff losses and ensure business continuity.
In the run-up to Monday’s vote on the EMA’s future home, political horse-trading and vote-swapping behind the scenes makes it difficult to predict which EU city will win the prized agency.
The world of diabetes will increasingly be dominated by Novo Nordisk and Eli Lilly, the Danish group's chief science officer tells Scrip.
A UK Government report is spelling out an achievable vision for the country's life sciences sector which will create an internationally competitive eco-system.
The Medicines Manufacturing Industry Partnership says £140m invested in four centers would provide high-skilled jobs and make the UK the first place in the world where drugs can be discovered, made and packaged.
Ipsen's VP of commercial operations for the UK and Ireland outlines how the French company will use managed access programs to get drugs reimbursed on the NHS and describes Ipsen's plans for growth and greater investment in the UK, despite Brexit uncertainties.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.